Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

1. Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis Full Text available with Trip Pro

, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–22. 8. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;21(Suppl 41):46s–53s. 9. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for diagnosis, management and prevention of chronic obstructive lung disease: the GOLD science committee (...) , Hurst JR, Calverley PMA, Albert RK, Anzueto A, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49:1600791. 16. McCrory DC, Brown CD. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4:CD003900. 17. Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations

2020 BMC complementary medicine and therapies

2. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT Full Text available with Trip Pro

C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Point-of-care testing resulted in a 20% absolute reduction in patient-reported antibiotic consumption over 4 weeks, without impairing chronic obstructive pulmonary disease health status. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , & . Nick A Francis 1, * , David Gillespie 2 , Patrick White 3

2020 NIHR HTA programme

3. Do Antibiotics Improve Patient Outcomes in Acute Exacerbations of Chronic Obstructive Pulmonary Disease? Full Text available with Trip Pro

, and severity of COPD exacerbations. Thorax . 2002 ; 57 : 759–764 | | | , x 7 Seemungal, T., Harper-Owen, R., Bhowmik, A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med . 2001 ; 164 : 1618–1623 | | | , x 8 Sethi, S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon?. Proc Am Thorac Soc . 2004 ; 1 : 109–114 | | | , x 9 Bafadhel, M., McKenna, S (...) ., Frei, A., Steurer-Stey, C.A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev . 2018 ; 10 : CD010257 Limitations of this meta-analysis include no consideration of underlying chronic obstructive pulmonary disease severity across trials because of poor reporting of lung function and other parameters. Studies were not limited to patients with suspected bacterial infection, who demonstrate the greatest benefit from antibiotics. Thus, the lack

2020 Annals of Emergency Medicine Systematic Review Snapshots

4. Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review Full Text available with Trip Pro

Obstructive Pulmonary Disease: A Systematic Review Abstract American Journal of Respiratory and Critical Care Medicine 2020;201:A2328 Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review x B. Rangelov , x A.L. Young , x J. Jacob , x A.P. Cahn , x S. Lee , x F.J. Wilson , x D.J. Hawkes , x J.R. Hurst , 25 Broadway New York, NY 10004 (212) 315-8600 ATS Journals Services General Information Copyright © 1987-2020 American Thoracic Society, All Rights Reserved. (...) Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review | A66. A SHARPER IMAGE: NOVEL IMAGING METHODOLOGIES Cookies Notification This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Search Menu Connect With Us Search in: A66. A SHARPER IMAGE: NOVEL IMAGING METHODOLOGIES > > > Thoracic Imaging at Exacerbation of Chronic

2020 A66. A SHARPER IMAGE: NOVEL IMAGING METHODOLOGIES

5. Prediction Models for Exacerbations of COPD: A Qualitative Systematic Review and Critical Appraisal Full Text available with Trip Pro

Prediction Models for Exacerbations of COPD: A Qualitative Systematic Review and Critical Appraisal Prediction Models for Exacerbations of COPD: A Qualitative Systematic Review and Critical Appraisal | C34. CHRONIC AND ACUTE MANAGEMENT AND RESOURCE UTILIZATION FOR COPD Cookies Notification This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Search Menu Connect With Us Search in: C34. CHRONIC AND ACUTE MANAGEMENT AND RESOURCE UTILIZATION FOR COPD (...) > > > Prediction Models for Exacerbations of COPD: A Qualitative Systematic Review and Critical Appraisal Abstract American Journal of Respiratory and Critical Care Medicine 2020;201:A4810 Prediction Models for Exacerbations of COPD: A Qualitative Systematic Review and Critical Appraisal x S. Shuyuan , x Z. qingxin , x S. feng , 25 Broadway New York, NY 10004 (212) 315-8600 ATS Journals Services General Information Copyright © 1987-2020 American Thoracic Society, All Rights Reserved.

2020 C34. CHRONIC AND ACUTE MANAGEMENT AND RESOURCE UTILIZATION FOR COPD

6. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review Full Text available with Trip Pro

of TCM Cheng-xiang Wang Beijing University of TCM Mei Han Beijing University of TCM Corresponding Author DOI: License: This work is licensed under a CC BY 4.0 License. View the published version . Abstract Objective: To investigate the clinical characteristics between the frequent exacerbator with chronic bronchitis (FE-CB) phenotype and the non-exacerbator (NE) phenotype among patients with chronic obstructive pulmonary disease (COPD). Methods: We searched CNKI, Wan fang, Chongqing VIP, China (...) the published version . Abstract Objective: To investigate the clinical characteristics between the frequent exacerbator with chronic bronchitis (FE-CB) phenotype and the non-exacerbator (NE) phenotype among patients with chronic obstructive pulmonary disease (COPD). Methods: We searched CNKI, Wan fang, Chongqing VIP, China Biology Medicine disc, PubMed, Cochrane Library, and EMBASE databases for relevant studies published as of April 30, 2019. All studies that investigated COPD patients with the FE-CB

2020 Research Square

7. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review Full Text available with Trip Pro

of TCM Cheng-xiang Wang Beijing University of TCM Mei Han Beijing University of Traditional Chinese Medicine Corresponding Author DOI: License: This work is licensed under a CC BY 4.0 License. View the published version . Abstract Objective: To investigate the clinical characteristics between the frequent exacerbator with chronic bronchitis (FE-CB) phenotype and the non-exacerbator (NE) phenotype among patients with chronic obstructive pulmonary disease (COPD). Methods: We searched CNKI, Wan fang (...) the frequent exacerbator with chronic bronchitis (FE-CB) phenotype and the non-exacerbator (NE) phenotype among patients with chronic obstructive pulmonary disease (COPD). Methods: We searched CNKI, Wan fang, Chongqing VIP, China Biology Medicine disc, PubMed, Cochrane Library, and EMBASE databases for relevant studies published as of April 30, 2019. All studies that investigated COPD patients with the FE-CB and NE phenotypes and which qualified the inclusion criteria were included. Cross-Sectional

2020 Research Square

8. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review Full Text available with Trip Pro

of TCM Cheng-xiang Wang Beijing University of TCM Mei Han Corresponding Author DOI: License: This work is licensed under a CC BY 4.0 License. View the published version . Abstract Objective: To investigate the clinical characteristics between the frequent exacerbator with chronic bronchitis (FE-CB) phenotype and the non-exacerbator (NE) phenotype among patients with chronic obstructive pulmonary disease (COPD). Methods: We searched CNKI, Wan fang, Chongqing VIP, China Biology Medicine disc, PubMed (...) The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review | Research Square Browse Tools & Services Your Cart See the published version of this article

2020 Research Square

9. Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease. Full Text available with Trip Pro

Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is a global leading cause of morbidity and mortality, characterised by acute deterioration in symptoms. During these exacerbations, people are prone to developing alveolar hypoventilation, which may be partly caused by the administration of high inspired oxygen concentrations.To determine the effect of different inspired oxygen concentrations (...) ("high flow" compared to "controlled") in the pre-hospital setting (prior to casualty/emergency department) on outcomes for people with acute exacerbations of COPD (AECOPD).The Cochrane Airways Group Specialised Register, reference lists of articles and online clinical trial databases were searched. Authors of identified randomised controlled trials (RCTs) were also contacted for details of other relevant published and unpublished studies. The most recent search was conducted on 16 September 2019.We

2020 Cochrane

10. Chronic obstructive pulmonary disease: How should I diagnose an acute exacerbation of COPD?

, see the CKS topic on . Pneumothorax. Acute heart failure. Pleural effusion. Cardiac ischaemia or arrhythmia. For more information, see the CKS topics on and . Lung cancer. For more information, see the CKS topic on . Upper airway obstruction. Basis for recommendation The information on symptoms and differential diagnosis of an acute exacerbation of chronic obstructive pulmonary disease (COPD) is based on expert opinion in clinical guidelines Management of COPD exacerbations: a European Respiratory (...) and change in sputum colour. Other reported symptoms may include: Increased wheeze and chest tightness. Upper respiratory tract symptoms (for example cold or sore throat). Reduced exercise tolerance. Ankle swelling. Increased fatigue. Acute confusion. What else might it be? Conditions which may present with similar symptoms to an acute exacerbation of chronic obstructive pulmonary disease (COPD) include : Pneumonia. For more information, see the CKS topic on . Pulmonary embolism. For more information

2020 NICE Clinical Knowledge Summaries

11. Systematic review and meta-analysis of shenfu injection on treating acute exacerbation of chronic obstructive pulmonary disease Full Text available with Trip Pro

Feb 1];6:276-83. Available from: Introduction Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, which is characterized by persistent respiratory symptoms and airflow restriction due to exposure to toxic particles or gas. Acute exacerbation of COPD (AECOPD) refers to the continuous deterioration of the patient's condition beyond daily life and the need to change the basic medication. Usually, it is manifested as short-term cough, expectoration, shortness (...) that the efficacy of experimental group in the treatment of AECOPD is better than control group. Due to the limitation of the number and quality of included studies, this conclusion needs more high quality studies to confirm. "> Users Online: 38 REVIEW ARTICLE Year : 2020 | Volume : 6 | Issue : 3 | Page : 276-283 Systematic review and meta-analysis of shenfu injection on treating acute exacerbation of chronic obstructive pulmonary disease 1 , 2 , 2 , 2 , 2 1 Institute of Basic Research in Clinical Medicine

2020 World Journal of Traditional Chinese Medicine

12. Metoprolol for the Prevention of Acute Exacerbations of COPD. Full Text available with Trip Pro

Metoprolol for the Prevention of Acute Exacerbations of COPD. Observational studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings have not been confirmed in randomized trials.In this prospective, randomized trial, we assigned patients between the ages of 40 and 85 years who had COPD to receive either a beta-blocker (extended-release metoprolol) or placebo. All (...) the patients had a clinical history of COPD, along with moderate airflow limitation and an increased risk of exacerbations, as evidenced by a history of exacerbations during the previous year or the prescribed use of supplemental oxygen. We excluded patients who were already taking a beta-blocker or who had an established indication for the use of such drugs. The primary end point was the time until the first exacerbation of COPD during the treatment period, which ranged from 336 to 350 days, depending

2019 NEJM

13. Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD Full Text available with Trip Pro

Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructive pulmonary disease (COPD) frequently experience exacerbations. We postulated that inhalation of nebulised AAT would be an effective treatment.We randomly assigned 168 patients to receive twice-daily inhalations of 80 mg AAT solution or placebo for 50 weeks (...) . Patients used an electronic diary to capture exacerbations. The primary endpoint was time from randomisation to the first event-based exacerbation. Secondary endpoints included change in the nature of the exacerbation as defined by the Anthonisen criteria. Safety was also assessed.Time to first moderate or severe exacerbation was a median of 112 days (interquartile range (IQR) 40-211 days) for AAT and 140 days (IQR 72-142 days) for placebo (p=0.0952). The mean yearly rate of all exacerbations was 3.12

2019 EvidenceUpdates

14. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD: A Systematic Review Full Text available with Trip Pro

(on dyspnea), resistance training (on dyspnea and quality of life), early pulmonary rehabilitation commenced before hospital discharge during the initial most acute phase of exacerbation rather than the convalescence period (on dyspnea) and whole body vibration training (on quality of life). Vitamin D supplementation may improve quality of life (low SOE). Conclusions. Although chronic obstructive pulmonary disease is a common condition, the evidence base for most interventions in ECOPD remains limited (...) Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD Systematic Review October 11, 2019 3.1 MB Related Files This report is available in PDF only ( [3.05 MB]; [211.1 KB]; [298.6 KB]). People using assistive technology may not be able to fully access information in these files. For additional assistance, please . Purpose of Review To evaluate the effectiveness and harms of pharmacologic and nonpharmacologic treatments for exacerbations of chronic obstructive pulmonary

2019 Agency for Healthcare Research and Quality (AHRQ)

15. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

of Bias Appendix F. Results From Included Studies Appendix G. Results by Severity Appendix H. Adverse Events Appendix I. Inclusion and Exclusion Criteria of Included Studies Appendix J. Sensitivity Analysis Appendix K. Appendix References ES-1 Evidence Summary Background and Objectives Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by airflow limitation and chronic respiratory symptoms. The global prevalence is estimated to be greater than 10 percent (...) of experiencing exacerbations of COPD (ECOPD). There have been various definitions of what constitutes an ECOPD. The Global Initiative for chronic obstructive lung disease (GOLD) defines ECOPD in its 2019 report as “acute worsening of respiratory symptoms that result in additional therapy.” 5 ECOPD is generally characterized by increased dyspnea, increased frequency and severity of cough, and/or increased sputum production. 6 ECOPD is a leading independent cause of increased mortality and morbidity among

2019 Effective Health Care Program (AHRQ)

16. F1000Prime recommendation of Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. Full Text available with Trip Pro

more_vert close Download article Export article Sciwheel Download citation BibTeX RIS Share Email Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. ARTICLE PUBLISHED: 2015 CITE AS: PLoS ONE. 2015 ; 10 ( 3 ): e0121257 Recommendations Abstract Comments You have reached your article limit. Register for 30-day free trial Registration is free and only takes a moment, or subscribe for unlimited access. Already registered (...) F1000Prime recommendation of Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. Prophylactic use of macrolide antibiotics for the... | Faculty Opinions On April 12th, 2020, F1000Prime became Faculty Opinions. See our to learn more. Welcome Guest 1 Recommendations info_outline Systematic Review / Meta-analysis New Finding close Classified As New Finding 1 Article Type Systematic Review / Meta-analysis More

2019 Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

17. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review Full Text available with Trip Pro

of TCM Cheng-xiang Wang Beijing University of TCM Mei Han Corresponding Author DOI: License: This work is licensed under a CC BY 4.0 License. View the published version . Abstract Abstract Objective: To investigate the clinical characteristics between the frequent exacerbator with chronic bronchitis (FE-CB) phenotype and the non-exacerbator (NE) phenotype among patients with chronic obstructive pulmonary disease (COPD). Methods: We searched CNKI, Wan fang, Chongqing VIP, China Biology Medicine disc (...) : To investigate the clinical characteristics between the frequent exacerbator with chronic bronchitis (FE-CB) phenotype and the non-exacerbator (NE) phenotype among patients with chronic obstructive pulmonary disease (COPD). Methods: We searched CNKI, Wan fang, Chongqing VIP, China Biology Medicine disc, PubMed, Cochrane Library, and EMBASE databases for relevant studies published as of April 30, 2019. All studies that investigated COPD patients with the FE-CB and NE phenotypes and which qualified

2019 Research Square

18. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. Full Text available with Trip Pro

C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. Point-of-care testing of C-reactive protein (CRP) may be a way to reduce unnecessary use of antibiotics without harming patients who have acute exacerbations of chronic obstructive pulmonary disease (COPD).We performed a multicenter, open-label, randomized, controlled trial involving patients with a diagnosis of COPD in their primary care clinical record who consulted a clinician at 1 of 86 general medical (...) practices in England and Wales for an acute exacerbation of COPD. The patients were assigned to receive usual care guided by CRP point-of-care testing (CRP-guided group) or usual care alone (usual-care group). The primary outcomes were patient-reported use of antibiotics for acute exacerbations of COPD within 4 weeks after randomization (to show superiority) and COPD-related health status at 2 weeks after randomization, as measured by the Clinical COPD Questionnaire, a 10-item scale with scores ranging

2019 NEJM Controlled trial quality: predicted high

19. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions Full Text available with Trip Pro

CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease (COPD) is controversial and a biomarker identifying patients who benefit from antibiotics is mandatory. We performed a randomised, controlled trial in patients with acute exacerbations of COPD, comparing C-reactive protein (CRP)-guided antibiotic treatment to patient reported symptoms in accordance with the Global (...) Initiative for Chronic Obstructive Lung Disease (GOLD) strategy, in order to show a reduction in antibiotic prescription.Patients hospitalised with acute exacerbations of COPD were randomised to receive antibiotics based either on the GOLD strategy or according to the CRP strategy (CRP ≥50 mg·L-1).In total, 101 patients were randomised to the CRP group and 119 to the GOLD group. Fewer patients in the CRP group were treated with antibiotics compared to the GOLD group (31.7% versus 46.2%, p=0.028; adjusted

2019 EvidenceUpdates

20. [Effectiveness of a brief educational intervention relating to the correct use of inhalers on the prevention of exacerbation in patients suffering from chronic obstructive pulmonary disease]. Full Text available with Trip Pro

[Effectiveness of a brief educational intervention relating to the correct use of inhalers on the prevention of exacerbation in patients suffering from chronic obstructive pulmonary disease]. To predict the effect of a brief educational intervention aimed at improving the inhaler technique on the reduction of exacerbations in patients with COPD over a year.A triple blind, randomised controlled clinical trial with parallel design.to be between 40-75 years, having been diagnosed with COPD (...) of exacerbations in each group was checked.social and demographic, study, dyspnoea level, body-mass index, tobacco use, FEV1, FEV1/FVC, COPD stage, BODEX index, number, type, and inhaler technique, number of previous exacerbations. Bayesian inference analysis was performed using logistic regression models.A total of 56 patients were assigned to de intervention group and 41 to the control one. There were 16 and 14 lost to follow-up, respectively. In the intervention group, 44.6% of the patients had

2019 Semergen Controlled trial quality: uncertain